U.S. Semiconductors Stock News

If you are wondering whether Bitmine Immersion Technologies at around US$18.39 is priced for further gains or already running ahead of itself, the valuation story is the key place to focus. The share price has had a sharp mix of moves, with a 129.9% return over the last year sitting alongside a 41.0% year to date decline, a 3.1% decline over the past month and a 12.2% decline over the last week. These swings have put Bitmine Immersion Technologies squarely on the radar of investors who are...

Investors may be wondering whether Exxon Mobil's share price still offers value after a strong run, or whether most of the opportunity is already on the table. The stock last closed at US$170.99, with recent returns of 7.1% over 7 days, 12.1% over 30 days, 39.4% year to date and 50.2% over 1 year, which has likely caught the attention of both new and long term investors. These moves sit against a backdrop of ongoing attention on large integrated energy companies. This includes debates around...

Best Buy stock performance snapshot Best Buy (BBY) has seen mixed share performance, with the price down about 9% year to date and 8% over the past year, while the past month shows a modest positive return. See our latest analysis for Best Buy. The recent 1 month share price return of 1.63% contrasts with a weaker 3 month share price return of a 7.16% decline and a 1 year total shareholder return of an 8.17% decline, suggesting momentum has been fading rather than building. If you are...

Some Universal Insurance Holdings, Inc. ( NYSE:UVE ) shareholders may be a little concerned to see that the Executive...

NRx Pharmaceuticals, Inc. ( NASDAQ:NRXP ) is possibly approaching a major achievement in its business, so we would like...

A shareholder proposal seeks to cap executive severance at Capital One Financial (NYSE:COF) at 2.99 times base salary plus target bonus. The proposal would require shareholder approval for any senior manager pay package that exceeds this threshold. Capital One has filed a definitive proxy statement recommending that shareholders vote against the proposal at its May annual meeting. Capital One Financial, the parent of Capital One Bank, operates across credit cards, consumer lending, and...

Wondering whether Curtiss-Wright at around US$663 per share still offers value, or if most of the opportunity has already been priced in. The stock has recorded a 1 year return of 109.8% and a 3 year return of 279.6%. In contrast, the 7 day and 30 day returns of a 1.1% decline and a 5.3% decline hint at some recent cooling after a strong run. Over 5 years, Curtiss-Wright has delivered a very large total return of 463.7%. This naturally raises questions about what is now embedded in the...

If you are trying to figure out whether CRISPR Therapeutics is attractively priced or not, the recent share performance gives you a lot to think about. The stock last closed at US$45.75, with a 1.1% decline over 7 days, a 23.9% decline over 30 days, a 14.9% decline year to date, but a 23.7% gain over 1 year and a 1.1% gain over 3 years compared to a 61.7% decline over 5 years. These shifts in returns have kept CRISPR Therapeutics on many watchlists, as investors weigh shorter term weakness...

In March 2026, global talent solutions and consulting firm Robert Half was named by Fortune as one of America's Most Innovative Companies, highlighting its AI-powered tools and proprietary data-driven capabilities in improving talent matching and client support. This innovation recognition comes as Robert Half continues to contend with declining sales and earnings, underscoring a tension between its technology progress and current business headwinds. Now we will examine how this innovation...

If you are wondering whether Greif is offering fair value at its recent price, this breakdown will help you see how the current share level stacks up against several valuation checks. The stock recently closed at US$66.37, with a 6.0% return over the past 7 days, an 8.7% decline over 30 days, a 3.0% decline year to date, and a 25.2% gain over the past year, which may influence how you think about both upside potential and risk. Those swings sit alongside a longer track record, with returns...

Recent price action and business context Legence (LGN) has drawn fresh attention after a recent share price move, with the stock closing at US$54.75 and showing mixed short term returns over the past week, month and past 3 months. For readers tracking the underlying business, Legence reports US$2.55b in revenue across engineering, installation and maintenance services for mission critical building systems in the United States. These operations are supported by two segments: Engineering &...

If you are wondering whether e.l.f. Beauty at around US$61.05 is a bargain or already pricing in a lot of optimism, this breakdown will help you frame that question clearly. The share price has recently been under pressure, with a 15.8% decline over 7 days, a 33.7% decline over 30 days, and a 21.5% decline year to date, compared with a 5.8% decline over the last year and a 25.9% decline over 3 years. These moves come as investors continue to reassess the broader beauty and personal care...

If you are wondering whether Arista Networks' current share price lines up with its underlying value, you are not alone. This article walks through what the numbers actually say. The stock trades at US$120.77 after a 7 day return of an 8% decline and a 30 day return of a 9.5% decline, set against a 1 year return of 55% and a very large 5 year gain. Recent attention has focused on Arista Networks as investors weigh its role in networking and cloud infrastructure. Headlines frequently link the...

Recent performance snapshot Karman Holdings (KRMN) has drawn investor attention after a past year total return of about 140%, alongside a decline of nearly 5% over the past month and a gain of roughly 8% over the past three months. See our latest analysis for Karman Holdings. With the share price at $84.07, Karman Holdings has seen short term pressure, including a 15.4% decline in the 7 day share price return, while its 1 year total shareholder return of about 140% still signals strong longer...

Aerie parent American Eagle Outfitters (AEO) is back in focus after extending its "100% Aerie Real" campaign featuring Pamela Anderson. The move underscores a public stance against AI generated bodies and fully unretouched marketing. See our latest analysis for American Eagle Outfitters. Despite the renewed attention around Aerie’s authenticity push and American Eagle Outfitters’ presence at events like Shoptalk Spring 2026, the share price, now at $16.13, shows a 30 day share price return of...

Investors may be wondering if Signet Jewelers at around US$84 is still offering value, or if the easy money has already been made. The stock has pulled back recently, with a 5.6% decline over the last 7 days and a 12.6% decline over the last 30 days, even though the 1-year return sits at 45.1% and the 5-year return at 55.8%. This recent volatility comes after a period where Signet's share price performance over 3 years and 5 years has been positive overall. This can change how the market...

Tidewater (NYSE:TDW) director Darron M. Anderson will step down from the board at the 2026 Annual Meeting. The board will shrink from eight to seven members after Anderson’s planned departure. Anderson is not seeking reelection and is expected to serve out his current term on the Audit and Safety & Sustainability Committees. The company states his decision is not related to any disagreement with management or board policies. Tidewater comes into this board change with its shares at $82.4...

The leak of Anthropic's Claude Mythos model has put renewed pressure on application software stocks, and Atlassian (TEAM) was caught in this AI scare trade as investors reassessed sector margins. See our latest analysis for Atlassian. Beyond the latest AI jitters, Atlassian’s 1-day share price return of 4.4% and 7-day return of 11.7% sit within a much steeper 90-day share price decline of 60.3% and a 1-year total shareholder return of 70.1%. This signals pressure that has been building for...

Context for the Recent Move in Amicus Therapeutics (FOLD) Recent trading in Amicus Therapeutics (FOLD) puts the spotlight back on how investors are weighing its rare disease portfolio against current financial metrics, including revenue, profitability, and multi year total returns. See our latest analysis for Amicus Therapeutics. At a share price of US$14.41, recent trading has been fairly muted over days and weeks. However, the 1 year total shareholder return of 70.94% and 5 year total...

Recent share performance and business snapshot With no single event driving headlines, Chubb (CB) has still drawn attention after a recent share pullback. This has invited investors to reassess the insurer’s US$124.2b market value and diversified global operations. See our latest analysis for Chubb. Chubb’s recent 6.4% one month share price pullback contrasts with a 2.9% year to date share price gain and a 9.0% one year total shareholder return. This points to moderating short term momentum...

If you are wondering whether Nova's share price still offers value after a big run, or if you may be late to the story, this breakdown can help frame what the current market price might be implying. Nova closed at US$440.72, with returns of 26.9% year to date and 136.4% over the last year. Over the last 7 days and 30 days, the stock has seen more muted moves of a 5.3% decline and a 0.4% gain, respectively. Recent coverage around Nova has focused on its role in the semiconductor equipment...

Market reaction and governance changes set the stage Entegris (ENTG) quickly came into focus after sector wide selling linked to concerns over Google’s TurboQuant algorithm and its potential effect on memory demand, just as shareholders prepare to vote on governance changes. See our latest analysis for Entegris. At a share price of US$113.59, Entegris has seen a 30 day share price return of a 14% decline. However, its 90 day share price return of 32.17% and 1 year total shareholder return of...

Why Catalyst Pharmaceuticals (CPRX) is Back on Investors’ Radar Catalyst Pharmaceuticals (CPRX) has drawn attention after a mixed stretch in the stock, with a small month gain but a decline over the past 3 months and past year. This has prompted fresh interest in its fundamentals. See our latest analysis for Catalyst Pharmaceuticals. At a share price of US$23.40, Catalyst’s recent 1 day share price return of a 3.51% decline and 7 day gain of 2.68% contrast with a softer 1 year total...

Wondering if Deere at US$566.64 still offers value, or if most of the opportunity is already priced in. The stock's recent returns show a mixed picture, with a 1.2% gain over 7 days, a 10.0% decline over 30 days, and longer term returns of 21.4% year to date and 23.4% over 1 year. Recent news coverage has focused on Deere's role as a major machinery and equipment provider, which often puts the stock in the spotlight when investors reassess exposure to industrial and capital goods names. This...